NeoDynamics AB (publ) (“NeoDynamics” or the Company) hereby announces that the exercise price for warrants series TO2 (the “Warrants”) is SEK 0,02 per share. The exercise period for the Warrants begins on November 20, 2023, and runs up to and including December 1, 2023. The last day for trading in the Warrants is November 29, 2023.
NeoDynamics carried out a right issue of units during August 2023 (the “Right Issue”). Each unit issued in the Rights Issue consisted of six (6) shares and five (5) warrants of which two (2) are of series TO2, and three (3) are of series TO3, where each warrant gives the right to subscribe for one new share. The exercise period for the Warrants of serie TO2 begins, November 20, 2023. The Warrants were issued free of charge. If all Warrants are exercised, NeoDynamics will receive approximately SEK 3.9 million before issue costs.
The subscription price for the Warrants corresponding to 70 percent of the average volume-weighted share price of the Company’s share during the period from November 3, 2023, up to and including November 16, 2023, however, not less than SEK 0.02 per share, and not more than SEK 0.15. 70 percent of the volume-weighted average price during the measurement period was below SEK 0.02 and thus the subscription price is SEK 0.02.
Summary of instructions and important dates
Holders of Warrants who wish to exercise these to subscribe for shares shall give notice regarding such exercise at latest on December 1, 2023. Warrants that have not been exercised on or before December 1, 2023, expire without value. Holders who do not wish to exercise their Warrants may sell them. Trading with Warrants is ongoing up to and including November 29, 2023.
Detailed information and instructions for subscription
Exercise of nominee-registered Warrants
Holders of Warrants who have their holdings nominee-registered (holdings in securities custody services, investment savings accounts (ISK) or endowment insurances) must notify the exercise of Warrants by contacting their respective nominee and follow the nominee's instructions regarding subscription and payment. This should take place well before December 1, 2023, as different nominees have different processing times.
Exercise of directly registered Warrants
Holders of Warrants who have their holdings directly registered (holdings on a VP account) must notify the exercise of Warrants by filling in and submitting an application form for the exercise, so that the application form is received by the issuing agent, Nordic Issuing, no later than December 1, 2023.
The application form is available on the Company's, the issuing agent's and Redeye AB's respective websites (www.neodynamics.com, www.nordic-issuing.se, www.redeye.se). Please note that payment for the new shares must be received by Nordic Issuing no later than December 1, 2023, in accordance with the instructions on the application form.
Trading in TO2
Holders who do not wish to exercise their Warrants may sell them on Nasdaq First North. The Warrants are traded up to and including November 29, 2023, under the short name NEOD TO2 and with ISIN code SE0020552495. Warrants that are not exercised on December 1, 2023, at the latest will expire without value.
Outcome and delivery of new shares
The outcome of the exercise of Warrants will be published via a press release on or around December 5, 2023. Shares that have been subscribed and paid for may be registered on the subscriber's securities depository as interim shares (IA) until registration of the issue has been completed with the Swedish Companies Registration Office, whereupon the interim shares automatically will be converted into shares in NeoDynamics.
Increase in the number of shares and share capital
Upon full utilization of all 192,813,110 Warrants series TO2, the share capital will increase by a maximum of SEK 3,326,026.1475 to SEK 15,382,750.0140 SEK through the issuance of maximum of 192,813,110 new shares, resulting in that the total number of shares in the Company will increase from 698,940,514 to 891,753,624. Upon full utilization of all Warrants series TO2, the dilution of the shares amounts to approximately 22 percent.
Redeye AB is a financial advisor in connection with the Rights Issue. Advokatfirman Lindahl KB acts as legal advisor to NeoDynamics in connection with the Rights Issue. Nordic Issuing AB acts as the issuing agent in connection with the Rights Issue.
For further information, please contact:
Anna Eriksrud, CEO NeoDynamics AB, phone 708 444 966 or e-mail email@example.com
Aaron Wong, CFO NeoDynamics AB, phone 735 972 011 or e-mail firstname.lastname@example.org
NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. NeoNavia® is CE approved, and in September 2022, received a 510k approval from the FDA. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and launches in USA during 2023. NeoDynamic’s shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB.
NeoNavia® is the trade name for the complete biopsy system intended for use in ultrasound-guided sampling. NeoNavia® consists of a base unit, a hand unit, and three types of biopsy needles. The pulse technology drives the respective needle type, which facilitates needle insertion and placement in the suspected tumor. The system is designed to offer physicians and patients precise and robust tissue sampling for accurate diagnosis and individualized treatment.
About the pulse technology
The patented pulse technology is based on a pneumatically driven mechanism that enables high precision and control when inserting and positioning the biopsy needle, regardless of tissue type. The pneumatic drive unit that generates pulses is located in a hand-held instrument. With power from the base unit, the hand-held driver accelerates the biopsy needle with great control, even over short distances, enabling a distinct step-by-step insertion without affecting the surrounding tissue. This enables good access and flexibility in sampling, even in tiny and tricky localized tumors.
For more information, please visit Neodynamics.com.
The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in NeoDynamics. The invitation to the persons concerned to subscribe for units consisting of shares and warrants in NeoDynamics has only been made through the prospectus published by NeoDynamics on July 31, 2023, and through the supplement prospectuses published by NeoDynamics on August 11, 2023. The prospectuses have been approved and registered by the Swedish Financial Supervisory Authority and have been published on the Company’s website, www.neodynamics.com.
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.